In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axikin Pharmaceuticals, Inc.

Latest From Axikin Pharmaceuticals, Inc.

Dealmaking When Pharma's the Only Game in Town

With no public market to provide competition, the theory among biotech's optimists was that Big Pharma would step in and buy lots of bargains. But cheap prices and easy availability haven't increased drug company appetites: They will only buy what they really want. Deal volumes, both for M&A and alliances, are falling, while Big Pharma has learned to put more of the risk back on biotech. What will change this dynamic, putting more bargaining into biotech hands, is the revival of the public market - and there are hints that such a revival may be on the way.

BioPharmaceutical Strategy

Selected Start-Ups (02/2009)

In Vivo briefly describes these recently founded companies: Axikin Pharmaceuticals, Garnet BioTherapeutics, Medimetriks Pharmaceuticals, Nexomics Biosciences, OrthAlign and Promentis Pharmaceuticals.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register